Heart failure, diabetes and the thiazolidinediones: an unfolding story

Review: thiazolidinediones increase risk of heart failure in type 2 diabetes.

Risk of Heart Failure with the Use of Thiazolidinediones within a Medicaid Population

Objective: Controlling for demographic and clinical characteristics and drug exposure, we evaluated the risk of heart failure after the use of thiazolidinediones (TZDs) in a group of Medicaid beneficiaries. We explored the effects of demographics, including race, clinical characteristics, treatment with drugs commonly given to patients with diabetes or heart failure, and the duration of drug th...

Metformin and thiazolidinedione use in Medicare patients with heart failure.

CONTEXT According to package inserts, metformin is contraindicated in diabetic patients receiving drug treatment for heart failure therapy, and thiazolidinediones are not recommended in diabetic patients with symptoms of advanced heart failure. Little is known about patterns of use of these antihyperglycemic drugs in diabetic patients with heart failure. OBJECTIVE To determine the proportions...

Thiazolidinediones and heart failure: a teleo-analysis.

OBJECTIVE Thiazolidinediones (TZDs) are known to increase the risk of heart failure in patients with type 2 diabetes. We aimed to evaluate the magnitude of the risk of heart failure with TZDs and classify this adverse effect under the novel dose-time-susceptibility system. RESEARCH DESIGN AND METHODS Evidence from randomized trials, controlled observational studies, anecdotal case reports, ca...

Type 2 diabetes, thiazolidinediones, and cardiovascular risk.

Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achieving adequate glycaemic control is an important aim of therapy. Thiazolidinediones, or glitazones, have been used for the treatment of diabetes for a decade. Rosiglitazone and pioglitazone are currently available, however recent concerns around cardiovascular safety have led to restrictions on their...